Immune cell boost plus targeted procedure shows promise for inoperable liver tumors

NCT ID NCT07209813

Not yet recruiting Disease control Sponsor: Beijing Gene Key Life Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding a special immune cell infusion (GKL-006) to a standard procedure that blocks blood flow to tumors (TACE) can shrink liver cancers that cannot be removed by surgery. About 48 adults with unresectable hepatocellular carcinoma will receive the combination or TACE alone. The main goal is to see how many patients' tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GKL-006 (a type of immune cell called iNKT cells) given as an infusion, combined with TACE (a procedure that blocks blood flow to the tumor)
What this could lead to: If successful, this combination could offer a new way to shrink or control liver tumors that cannot be surgically removed, potentially extending life or making transplant possible.
What could go wrong: This is an early Phase 2 trial with only 48 people, so results may not apply to everyone. The treatment may cause side effects or fail to improve outcomes compared to TACE alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.